Baird Financial Group
ASND icon

Baird Financial Group’s Ascendis Pharma A/S ASND Stock Holding History

Baird Financial Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$395K – 1854
2021
Q2 		$395K Buy
+3,000
New +$400K ﹤0.01% 1486

Other funds holding ASND

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Baird Financial Group's ASND Position: Q3 2021 in Review

Baird Financial Group sold out of Ascendis Pharma A/S (ASND) in Q3 2021, closing a stake of 3,000 shares — an estimated $395K sold.

Baird Financial Group first reported a position in ASND in Q2 2021 and held it in 1 quarter. The position peaked at $395K in Q2 2021. 166 funds tracked by Wall St. Rank hold ASND as of Q3 2021.

  • Baird Financial Group reported no remaining Ascendis Pharma A/S position as of Q3 2021 after selling out during the quarter.
  • Baird Financial Group sold 3,000 Ascendis Pharma A/S shares in Q3 2021, an estimated $395K.
  • Baird Financial Group first reported a position in Ascendis Pharma A/S in Q2 2021 and held it in 1 quarter.
  • Baird Financial Group's Ascendis Pharma A/S position peaked at $395K in Q2 2021.
  • 166 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2021.

Based on Baird Financial Group's 13F filing for Q3 2021, filed 12 Nov 2021.